Results 121 to 130 of about 820 (140)

A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A

Journal of Thrombosis and Haemostasis, 2023
Kagehiro Amano, Satoshi Higasa, Yoshinobu Seki   +2 more
exaly  

Detailed analysis of anti‐emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A

Journal of Thrombosis and Haemostasis, 2021
Makoto Kaneda, Ryohei Kawasaki, Tetsuhiro Soeda   +2 more
exaly  

Low immunogenicity of emicizumab in persons with haemophilia A

Haemophilia, 2021
Christophe Schmitt, Sammy Chebon, Markus Niggli   +2 more
exaly  

Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring

Haemophilia, 2021
Assaf Arie Barg, Ivan Budnik, Einat Avishai   +2 more
exaly  

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

Haemophilia, 2022
Anna Kiialainen, Markus Niggli, Christine L Kempton   +2 more
exaly  

Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors

Haemophilia, 2020
Frederico Xavier, Craig D Seaman
exaly  

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data

Haemophilia, 2021
Mudi Misgav, Ivan Budnik, Einat Avishai   +2 more
exaly  

Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab

Arteriosclerosis, Thrombosis, and Vascular Biology, 2020
Koji Yada, Keiji Nogami
exaly  

Cost‐utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada

Haemophilia, 2023
Jacky K Yu, William W L Wong, Arun Keepanasseril   +2 more
exaly  

Emicizumab treatment and monitoring in a paediatric cohort: real‐world data

British Journal of Haematology, 2020
Assaf Arie Barg, Tami Livnat, Ivan Budnik   +2 more
exaly